AAAAAA

   
Results: 1-14 |
Results: 14
Optimization of a screening lead for factor VIIa/TF
Authors: Young, WB Kolesnikov, A Rai, R Sprengeler, PA Leahy, EM Shrader, WD Sangalang, J Burgess-Henry, J Spencer, J Elrod, K Cregar, L
Citation: Wb. Young et al., Optimization of a screening lead for factor VIIa/TF, BIOORG MED, 11(17), 2001, pp. 2253-2256
Development of potent and selective factor Xa inhibitors
Authors: Rai, R Kolesnikov, A Li, Y Young, WB Leahy, E Sprengeler, PA Verner, E Shrader, WD Burgess-Henry, J Sangalang, JC Allen, D Chen, X Katz, BA Luong, C Elrod, K Cregar, L
Citation: R. Rai et al., Development of potent and selective factor Xa inhibitors, BIOORG MED, 11(14), 2001, pp. 1797-1800
Neutral inhibitors of the serine protease factor Xa
Authors: Shrader, WD Young, WB Sprengeler, PA Sangalang, JC Elrod, K Carr, G
Citation: Wd. Shrader et al., Neutral inhibitors of the serine protease factor Xa, BIOORG MED, 11(14), 2001, pp. 1801-1804
Perspectives on factor Xa inhibition
Authors: Rai, R Sprengeler, PA Elrod, KC Young, WB
Citation: R. Rai et al., Perspectives on factor Xa inhibition, CURR MED CH, 8(2), 2001, pp. 101-119
A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site
Authors: Katz, BA Elrod, K Luong, C Rice, MJ Mackman, RL Sprengeler, PA Spencer, J Hataye, J Janc, J Link, J Litvak, J Rai, R Rice, K Sideris, S Verner, E Young, W
Citation: Ba. Katz et al., A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site, J MOL BIOL, 307(5), 2001, pp. 1451-1486
Exploiting subsite S1 of trypsin-like serine proteases for selectivity: Potent and selective inhibitors of urokinase-type plasminogen activator
Authors: Mackman, RL Katz, BA Breitenbucher, JG Hui, HC Verner, E Luong, C Liu, L Sprengeler, PA
Citation: Rl. Mackman et al., Exploiting subsite S1 of trypsin-like serine proteases for selectivity: Potent and selective inhibitors of urokinase-type plasminogen activator, J MED CHEM, 44(23), 2001, pp. 3856-3871
Development of serine protease inhibitors displaying a multicentered short(< 2.3 angstrom) hydrogen bond binding mode: Inhibitors of urokinase-type plasminogen activator and factor Xa
Authors: Verner, E Katz, BA Spencer, JR Allen, D Hataye, J Hruzewicz, W Hui, HC Kolesnikov, A Li, Y Luong, C Martelli, A Radika, K Rai, R She, M Shrader, W Sprengeler, PA Trapp, S Wang, J Young, WB Mackman, RL
Citation: E. Verner et al., Development of serine protease inhibitors displaying a multicentered short(< 2.3 angstrom) hydrogen bond binding mode: Inhibitors of urokinase-type plasminogen activator and factor Xa, J MED CHEM, 44(17), 2001, pp. 2753-2771
Design, synthesis, and evaluation of a pyrrolinone-based matrix metalloprotease inhibitor
Authors: Smith, AB Nittoli, T Sprengeler, PA Duan, JJW Liu, RQ Hirschmann, RF
Citation: Ab. Smith et al., Design, synthesis, and evaluation of a pyrrolinone-based matrix metalloprotease inhibitor, ORG LETT, 2(24), 2000, pp. 3809-3812
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator
Authors: Katz, BA Mackman, R Luong, C Radika, K Martelli, A Sprengeler, PA Wang, J Chan, HD Wong, L
Citation: Ba. Katz et al., Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator, CHEM BIOL, 7(4), 2000, pp. 299-312
Design, synthesis, and solution structure of a pyrrolinone-based beta-turnpeptidomimetic
Authors: Smith, AB Wang, WY Sprengeler, PA Hirschmann, R
Citation: Ab. Smith et al., Design, synthesis, and solution structure of a pyrrolinone-based beta-turnpeptidomimetic, J AM CHEM S, 122(44), 2000, pp. 11037-11038
The crystal structure of a pyrrolinone-peptide hybrid ligand bound to the human class II MHC protein HLA-DR1
Authors: Lee, KH Olson, GL Bolin, DR Benowitz, AB Sprengeler, PA Smith, AB Hirschmann, RF Wiley, DC
Citation: Kh. Lee et al., The crystal structure of a pyrrolinone-peptide hybrid ligand bound to the human class II MHC protein HLA-DR1, J AM CHEM S, 122(35), 2000, pp. 8370-8375
Molecular modeling, synthesis, and structures of N-methylated 3,5-linked pyrrolin-4-ones toward the creation of a privileged nonpeptide scaffold
Authors: Smith, AB Favor, DA Sprengeler, PA Guzman, MC Carroll, PJ Furst, GT Hirschmann, R
Citation: Ab. Smith et al., Molecular modeling, synthesis, and structures of N-methylated 3,5-linked pyrrolin-4-ones toward the creation of a privileged nonpeptide scaffold, BIO MED CH, 7(1), 1999, pp. 9-22
Design and synthesis of a competent pyrrolinone-peptide hybrid ligand for the class II major histocompatibility complex protein HLA-DR1
Authors: Smith, AB Benowitz, AB Sprengeler, PA Barbosa, J Guzman, MC Hirschmann, R Schweiger, EJ Bolin, DR Nagy, Z Campbell, RM Cox, DC Olson, GL
Citation: Ab. Smith et al., Design and synthesis of a competent pyrrolinone-peptide hybrid ligand for the class II major histocompatibility complex protein HLA-DR1, J AM CHEM S, 121(40), 1999, pp. 9286-9298
Design, synthesis, and evaluation of a pyrrolinone-peptide hybrid ligand for the class II MHC protein HLA-DR1
Authors: Smith, AB Benowitz, AB Guzman, MC Sprengeler, PA Hirschmann, R Schweiger, EJ Bolin, DR Nagy, Z Campbell, RM Cox, DC Olson, GL
Citation: Ab. Smith et al., Design, synthesis, and evaluation of a pyrrolinone-peptide hybrid ligand for the class II MHC protein HLA-DR1, J AM CHEM S, 120(48), 1998, pp. 12704-12705
Risultati: 1-14 |